The CAR-T therapy targeting CD19 positive B-cell acute lymphocytic leukemia (ALL) represents a significant advancement in the treatment of CNS leukemia, a challenging subset of ALL. Given the high unmet medical need and the limited treatment options available for CNS involvement, this therapy could capture a substantial market share if proven effective. The collaboration with The First Affiliated Hospital of Soochow University may enhance credibility and facilitate patient recruitment. However, the competitive landscape includes established CAR-T therapies, necessitating a focus on differentiating efficacy and safety profiles. Ongoing diligence is required to monitor regulatory pathways and potential market entry timelines, particularly as the trial is currently in the recruiting phase with an estimated completion date in late 2025.